Multiple System Atrophy (MSA) Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)

Multiple System Atrophy (MSA) Market is Segmented By Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Competitive overview of Multiple System Atrophy (MSA) Market

Les principaux acteurs du marché de l'atrophie des systèmes multiples (AMS) sont Merck & Co., Neuropore Therapies Inc., Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc., Stealth BioTherapeutics Corp., AFFiRiS AG, Corestem Inc., MitoDys Therapeutics Ltd., Modag GmbH, Acadia Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company et Johnson & Johnson.

Multiple System Atrophy (MSA) Market Leaders

  • Chelsea Therapeutics International, Ltd.
  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Société d'assurance-vie
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
*Disclaimer: Major players are listed in no particular order.

Multiple System Atrophy (MSA) Market - Competitive Rivalry, 2023

Market Concentration Graph

Multiple System Atrophy (MSA) Market

Market Consolidated
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
*Source: Coherent Market Insights

Multiple System Atrophy (MSA) Market Report Snapshots

Buy Now